1102 related articles for article (PubMed ID: 27388233)
1. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
2. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
4. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
[TBL] [Abstract][Full Text] [Related]
5. Circulating Biomarkers in Non-Small-Cell Lung Cancer: Current Status and Future Challenges.
Matikas A; Syrigos KN; Agelaki S
Clin Lung Cancer; 2016 Nov; 17(6):507-516. PubMed ID: 27373516
[TBL] [Abstract][Full Text] [Related]
6. Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer.
Gray J; Thompson JC; Carpenter EL; Elkhouly E; Aggarwal C
Oncologist; 2021 Oct; 26(10):e1812-e1821. PubMed ID: 34216176
[TBL] [Abstract][Full Text] [Related]
7. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations.
Esposito A; Criscitiello C; Trapani D; Curigliano G
Curr Oncol Rep; 2017 Jan; 19(1):1. PubMed ID: 28110461
[TBL] [Abstract][Full Text] [Related]
8. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
9. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy: A potential and promising diagnostic tool for advanced stage non-small cell lung cancer patients.
Doval DC; Deshpande R; Dhabhar B; Babu KG; Prabhash K; Chopra R; Sripada PV; Deshmukh C; Suryavanshi M
Indian J Cancer; 2017 Dec; 54(Supplement):S25-S30. PubMed ID: 29292705
[TBL] [Abstract][Full Text] [Related]
11. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
13. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
Ai B; Liu H; Huang Y; Peng P
Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
[TBL] [Abstract][Full Text] [Related]
14. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages.
Guibert N; Pradines A; Favre G; Mazieres J
Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167
[TBL] [Abstract][Full Text] [Related]
15. Letter to the Editor: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Nicolazzo C; Raimondi C; Loreni F; Gazzaniga P; Gradilone A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629196
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
18. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
19. Reply to the Letter to the Editor by C. Nicolazzo et al.: "Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy".
Alama A; Coco S; Vanni I; Grossi F
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28629197
[TBL] [Abstract][Full Text] [Related]
20. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]